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Abstract
Vaccines are rigorously tested and monitored and are among the safest medical products we use. 
Millions of vaccinations are given to children and adults in the United States each year. Serious 
adverse reactions are rare. However, because of the high volume of use, coincidental adverse 
events including deaths, that are temporally associated with vaccination, do occur. When death 
occurs shortly following vaccination, loved ones and others might naturally question whether it 
was related to vaccination. A large body of evidence supports the safety of vaccines, and multiple 
studies and scientific reviews have found no association between vaccination and deaths except in 
rare cases. During the US multi-state measles outbreak of 2014–2015, unsubstantiated claims of 
deaths caused by measles, mumps, and rubella (MMR) vaccine began circulating on the Internet, 
prompting responses by public health officials to address common misinterpretations and misuses 
of vaccine safety surveillance data, particularly around spontaneous reports submitted to the US 
Vaccine Adverse Event Reporting System (VAERS). We summarize epidemiologic data on deaths 
following vaccination, including examples where reasonable scientific evidence exists to support 
that vaccination caused or contributed to deaths. Rare cases where a known or plausible theoretical 
risk of death following vaccination exists include anaphylaxis, vaccine-strain systemic infection 
after administration of live vaccines to severely immunocompromised persons, intussusception 
after rotavirus vaccine, Guillain-Barré syndrome after inactivated influenza vaccine, fall-related 
injuries associated with syncope after vaccination, yellow fever vaccine-associated viscerotropic 
disease or associated neurologic disease, serious complications from smallpox vaccine including 
eczema vaccinatum, progressive vaccinia, postvaccinal encephalitis, myocarditis, and dilated 
cardiomyopathy, and vaccine-associated paralytic poliomyelitis from oral poliovirus vaccine. 
However, making general assumptions and drawing conclusions about vaccinations causing deaths 
based on spontaneous reports to VAERS – some of which might be anecdotal or second-hand – or 
case reports in the media, is not a scientifically valid practice.
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Modern vaccines are among the greatest public health achievements in history, preventing 
thousands of illnesses and deaths each year in the United States alone [1]. However, as 
illness, disability and death from vaccine-preventable diseases have decreased, concerns 
over vaccine safety have increased [2]. Despite the reality that a person is far more likely to 
be seriously or fatally injured by a disease prevented by vaccines than by a vaccine itself, 
there appears to be a trend towards increased refusal or delay of recommended vaccinations 
due to perceived safety concerns [3].
During the US multi-state measles outbreak of 2014–2015, most infected persons were not 
vaccinated against measles or had unknown vaccination status [4]. Early on, unsubstantiated 
claims of deaths caused by the measles, mumps, and rubella (MMR) vaccine began 
circulating on the Internet [5–7]. The original claim was based on data from the US Vaccine 
Adverse Event Reporting System (VAERS). It is important to realize, however, that VAERS 
is a voluntary reporting system which accepts any submitted report of an adverse event 
without judging its clinical significance or whether it was caused by a vaccination [8]. 
VAERS is a signal detection and hypothesis generating passive surveillance system and 
therefore any broad claim of cause and effect with respect to deaths following vaccination 
based on VAERS reports should not be interpreted as proof of causality.
We summarize historical information and published epidemiologic data on deaths following 
vaccination, including events where reasonable scientific evidence exists to conclude that 
vaccination caused or contributed to deaths. There are instances where medical errors or 
other human factors, not the vaccine as it was meant to be used, have caused deaths 
following vaccination [9,10]. However, our summary is restricted to deaths possibly related 
to the vaccine itself.
2. Historical events
In the era of modern medicine, some of the first concerns about vaccines causing death date 
to isolated, but high profile past vaccine safety incidents. The “Cutter Incident” in 1955 
involved a flaw in the Salk polio vaccine manufacturing process at Cutter Laboratories that 
led to production of substantial amounts of what was thought to be inactivated vaccine that 
contained live poliovirus. The result has been called “…one of the worst pharmaceutical 
disasters in US history”[11], with 40,000 cases of polio resulting in 51 cases of permanent 
paralysis and five deaths among vaccinated individuals, and 113 cases of paralysis and five 
deaths among contacts of vaccinated individuals [11,12]. As a result of the Cutter Incident, 
the US government implemented much more vigilant monitoring and regulation of the 
vaccine industry [13]. The Food and Drug Administration (FDA) now requires extensive 
testing to evaluate the safety and efficacy of vaccines prior to licensure. After licensure, 
FDA requires ongoing lot-release testing and manufacturing facility inspections. 
Additionally, manufacturers are required to conduct post-licensure safety monitoring for 
their products and report to the FDA [14,15].
In 1976, concerns in the United States about a possible influenza pandemic involving a virus 
similar to the deadly 1918 pandemic strain resulted in a large-scale vaccination program for 
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the entire country. Approximately 45 million people were vaccinated in 10 weeks with what 
became known as the “swine flu vaccine” [16]. The US government abruptly stopped the 
vaccination program when no swine flu cases were detected outside the military base where 
the disease originated and when an unexpectedly high number of cases of Guillain-Barré 
syndrome were reported in vaccinated individuals. The vaccine was estimated to have 
caused approximately one Guillain-Barré syndrome case per 100,000 persons vaccinated 
[17], resulting in 53 deaths [18]. As a result of the association between the 1976 swine flu 
vaccine and Guillain-Barré syndrome, this condition is closely monitored every influenza 
season as part of the influenza vaccine safety monitoring in the United States.
3. Current epidemiologic data on death associated with vaccination
Multiple large reviews and studies have been conducted to evaluate the association between 
vaccination and death. The results have consistently been reassuring. The Institute of 
Medicine (IOM) reviewed deaths reported to VAERS after childhood vaccines in the early 
1990s [19]. Some of the reports did not have enough information to make a determination 
about causality, but among reports with adequate follow-up, the IOM concluded that the vast 
majority of reported deaths were coincidental and not causally related to vaccination. There 
was one death due to a vaccine strain viral infection: a 3-month-old infant died from 
myocarditis after oral polio vaccine (which is no longer licensed for use in the United States) 
and DTP vaccine; vaccine strain poliovirus was isolated from the child’s myocardium. In 
another review of 1,266 deaths reported to VAERS from 1990–1997, nearly half of the 
deaths were due to sudden infant death syndrome (SIDS) with a peak in 1992–1993 and a 
decline after the “Back to Sleep” campaign was implemented [20]. The study also found that 
death reports to VAERS from causes other than SIDS also declined from 1993 to 1996 as 
the population and the number of vaccines administered increased, which was reassuring. In 
addition to SIDS, there were multiple causes of death which were not vaccine related, 
including infectious, congenital, neoplastic, cardiac, and cases with unknown causes due to 
incomplete information. This review also found that among the death reports, a higher 
percent of the infants had low birth weight than in the general US population (16.8% vs. 
7.2%); lower birth weight infants are known to have higher mortality rates during the first 2 
years of life [20]. Multiple other published reviews of VAERS data for specific vaccines and 
vaccine types have found no concerning patterns that would suggest a causal relationship 
between vaccination and deaths [21–26].
In 2003, the IOM examined the relationship between vaccinations and SIDS. The IOM 
rejected a causal association between the whole cell pertussis-containing vaccine (which is 
no longer in use in the United States) and SIDS and between exposure to multiple vaccines 
and SIDS. The IOM concluded that inadequate evidence existed to accept or reject a causal 
relationship between several other vaccines and SIDS. Additionally, the IOM did “… not 
recommend a policy review of the recommended childhood vaccination schedule by any of 
the national or federal vaccine advisory bodies on the basis of concerns about sudden 
unexpected death in infancy” [27].
A study published in 2013 using electronic health record databases reviewed health 
information on over 13 million vaccinated persons and compared causes of death in the 
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vaccinated study population to the general US population. The death rate 1 or 2 months 
following vaccination was lower than that in the general US population, and the causes of 
death were similar [28]. This study provides convincing evidence that vaccinations are not 
associated with an increased risk of death at the population level.
4. Evidence in favor of causal associations between vaccination and death
Although the evidence supports the safety of vaccines, there are rare instances where causal 
relationships between vaccination and death have been established or a plausible theoretical 
risk exists.
4.1 Anaphylaxis following vaccination
Many vaccines have been determined to rarely cause anaphylaxis. The risk of anaphylaxis is 
less than two cases per million doses of vaccines administered to children and adolescents 
[29]. While anaphylaxis is serious and can be fatal, death and other complications can be 
prevented with rapid treatment using effective medications including epinephrine, 
corticosteroids and beta-agonists. A 10-year review of claims to the US National Vaccine 
Injury Compensation Program noted five cases of death from anaphylaxis after vaccinations 
[30]. Another study published in 2003 using electronic health record databases found that 
after 7,644,049 doses of vaccination in children and adolescents, there were five possible 
cases of vaccine associated anaphylaxis and none resulted in death [29]. The Centers for 
Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices 
(ACIP) recommends screening patients for contraindications and precautions, including 
allergy history, prior to vaccination [31]. However, since anaphylaxis following vaccination 
is not always predictable or preventable, ACIP also recommends that healthcare providers 
be prepared to treat medical emergencies including anaphylaxis if they occur [31].
4.2 Severely immunocompromised persons receiving live vaccines
Live vaccine viruses are attenuated so they do not cause infection in individuals with intact 
immune systems. Live vaccines, however, are contraindicated for people who are severely 
immunocompromised [31] since their weakened immune systems may result in the live 
vaccine causing illness. Two published case reports describe immunocompromised children 
who received varicella vaccine, and where vaccine strain varicella zoster virus infection 
contributed to their deaths [32–33]. In one case, a 4-year-old child who had been in 
complete remission from acute lymphoblastic leukemia for 5 months received varicella 
vaccine during a 2-week break from chemotherapy [32]; in the other case, a 15-month-old 
did not have a diagnosis of being immunocompromised, but had failure to thrive and several 
hospitalizations beginning at 5 months of age for infections and respiratory problems 
requiring steroid treatment [33], indicating a possible undiagnosed immunodeficiency. There 
are at least six case reports of death among severely immunocompromised persons that have 
been linked to vaccine strain measles virus infection [34], including a case of vaccine 
associated pneumonitis in an immunocompromised person with HIV [35] and a case of 
measles inclusion-body encephalitis in a 21-month-old child with primary 
immunodeficiency [36]. CDC recommends screening prior to vaccination so that 
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contraindications and precautions, including previously diagnosed immune system problems 
are identified [31].
4.3 Intussusception after rotavirus vaccine
Intussusception is a rare medical condition in which the bowel folds in, or telescopes, on 
itself. It can resolve on its own, but might also require medical treatment or in some cases 
surgery. In very rare instances, it can result in death (less than 1% of cases in developed 
countries) [37]. RotaShield®, the first licensed rotavirus vaccine, was withdrawn from use in 
1999 after a greater than expected number of reports of intussusception were detected in 
post-marketing surveillance [38]. The attributable risk of intussusception was estimated to 
be one case for every 4,670 to 9,474 infants vaccinated [39] and one intussusception death 
after RotaShield® was reported in the literature [40]. There is a small increased risk of 
intussusception associated with the rotavirus vaccines that are currently licensed and in use 
(RotaTeq® and Rotarix®), but the risk is substantially lower than for RotaShield® at 
approximately 1 case in 20,000 to 100,000 doses [41–43]. One study estimated that among a 
hypothetical 4.3 million US birth cohort followed to age 5 years, currently licensed rotavirus 
vaccines prevent 14 deaths, more than 53,000 hospitalizations and more than 169,000 
emergency room visits; by comparison the vaccines are estimated to result in an excess of 
0.2 deaths, 45 hospitalizations, and 13 short stay visits from vaccine associated 
intussusception [44]. A published review of VAERS reports for 2006–2012 for the two 
currently licensed rotavirus vaccines indicated two death reports from intussusception; 
however, definitive causal associations with vaccination were not established in either case 
[45].
4.4 Guillain–Barré syndrome after seasonal and 2009 H1N1 (pandemic) inactivated 
influenza vaccines
Guillain-Barré syndrome is a rare disorder in which a person’s own immune system 
damages peripheral nerve cells, causing muscle weakness and sometimes paralysis [46]. 
Most people recover fully from Guillain-Barré syndrome, but some may have permanent 
nerve damage. Known risk factors for GBS include bacterial or viral infections, especially 
Campylobacter jejuni [47] and other infections causing diarrhea or respiratory illnesses [46]. 
Studies assessing the risk of Guillain-Barré syndrome after seasonal inactivated influenza 
vaccine since 1976 have shown either no risk or a small increased risk on the order of one to 
two cases per million doses administered [48], which is similar to the risk observed with the 
2009 influenza A (H1N1) monovalent vaccine [49]. However, one study found the 
cumulative risk of GBS over the entire influenza season was lower in individuals that 
received 2009 H1N1 (pandemic) inactivated influenza vaccines compared to unvaccinated 
individuals, indicating that vaccination might prevent GBS cases [50]. Another study using 
electronic health record data from 2000 through 2009 found that among 38 confirmed or 
probable GBS cases that occurred within 6 weeks of seasonal inactivated influenza vaccine, 
two deaths occurred during a median follow-up time of 6½ months; in neither of the cases 
that resulted in death was a causal association established with vaccination [51]. 
Approximately 5% of Guillain-Barré syndrome cases are fatal [52], but given the 
indeterminate association between influenza vaccination and GBS, risk of death from 
vaccine-associated GBS would have to be considered theoretical.
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4.5 Syncope (fainting) after vaccination leading to head trauma and death
The IOM concluded that the available evidence convincingly supports a causal relationship 
between the injection of a vaccine and syncope [53], although this relationship exists for any 
medical procedure involving a needle stick (e.g., blood draw). In a study on quadrivalent 
human papillomavirus vaccine among young women, 15% reported presyncope or syncope 
after the first dose [54]. Post-vaccination syncope can result in injuries including head 
trauma. A VAERS case report described an incident of death attributed to blunt head trauma 
following a fall secondary to vasovagal syncope that occurred several minutes after 
vaccination with hepatitis B vaccine [55]. Syncope is an acute event that typically occurs 
within 15 minutes of vaccination [56], and the Advisory Committee on Immunization 
Practices suggests a 15-minute observation period after vaccination, especially if the patient 
is an adolescent [31].
4.6 Yellow fever vaccine-associated viscerotropic and neurologic disease
A rare, serious reaction to yellow fever vaccine called yellow fever vaccine-associated 
viscerotropic disease has similar symptoms to yellow fever illness. Initial symptoms, which 
usually occur within 1 week of vaccination, are fever, along with feeling generally unwell, 
muscle pain, nausea, vomiting, and/or diarrhea. These symptoms can progress to 
multisystem organ failure and death. More than 60 cases worldwide have been reported to 
CDC and of those, 63% resulted in death [57]. The incidence of yellow fever vaccine-
associated viscerotropic disease in the United States is 0.4 cases per 100,000 doses 
administered [57].
Another rare reaction to yellow fever vaccine is yellow fever vaccine-associated neurologic 
disease. This includes several conditions, such as meningoencephalitis (inflammation of the 
brain and its membranes), Guillain-Barré syndrome, acute disseminated encephalomyelitis 
(inflammation of the brain and spinal cord), and bulbar palsy (paralysis of the motor units of 
the cranial nerves). Less than one case per 100,000 vaccine doses administered is reported, 
and it is rarely fatal [57].
Both yellow fever vaccine-associated viscerotropic and neurologic disease are more 
common in in persons aged 60 years or older [57], therefore age 60 years or older is a 
precaution to receiving this vaccine. In the United States, yellow fever vaccine is 
recommended only for travelers who plan to visit areas where the disease is present and for 
laboratory personnel who work with yellow fever virus [58].
4.7 Complications from smallpox vaccine
Serious adverse reactions and complications from smallpox vaccine can result in death in 
rare cases [59]. Based on historical data, the death rate following smallpox vaccination is 
approximately one death per million persons receiving an initial dose and one death per four 
million among persons receiving another dose after the first dose [60]. Death has also 
occurred among non-vaccinated persons who had accidental contact with vaccination sites 
of vaccine recipients [60]. Reactions that can cause or contribute to death include eczema 
vaccinatum, progressive vaccinia, postvaccinal encephalitis, myocarditis, and dilated 
cardiomyopathy. Additionally, vaccination of pregnant women can cause fetal infection 
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resulting in stillbirth or infant death [59,60]. Patients should be carefully screened for 
precautions and contraindications prior to receipt of smallpox vaccine [61]. In 2008, a new 
smallpox vaccine, ACAM2000™ replaced the previously used vaccine Dryvax®. The data 
indicate that ACAM2000™ has a similar safety profile to Dryvax® [61,62]. Naturally 
occurring smallpox disease has been eliminated worldwide, and in the United States, 
smallpox vaccine is currently only given to military personnel and selected individuals that 
might be at high risk of exposure, such as laboratory scientists that work with smallpox or 
similar viruses [63].
4.8 Vaccine-associated paralytic poliomyelitis from oral poliovirus vaccine
Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse reaction that can occur 
in a recipient of oral poliovirus vaccine (OPV) or in a contact of a recipient of OPV [64]. It 
can occur in healthy persons and in persons with immune system abnormalities. OPV is no 
longer used in the Unites States and has been replaced with inactivated poliovirus vaccine, 
but OPV is still used in many parts of the world. A recent review puts the risk of VAPP at 
around 4.7 cases per million births with an estimated 498 cases annually worldwide [65]. 
VAPP can result in death, but this is rare [66]. In the United States, from 1980–1989 there 
were 80 VAPP cases reported and among these reported cases, two patients (3%) died 
within 60 days after onset of paralysis [67].
5. Conclusion
Vaccines are rigorously tested and monitored and are among the safest medical products in 
use. Millions of vaccinations are administered to children and adults in the United States 
each year. Serious adverse reactions are uncommon and deaths caused by vaccines are very 
rare. Healthcare providers can take specific actions to help prevent adverse reactions, 
including proper screening for contraindications and precautions and observing a 15-minute 
waiting period after vaccinating to prevent fall-related injuries from syncope. CDC and FDA 
continuously monitor the safety of US licensed vaccines. All serious VAERS reports, 
including reports of death, are reviewed. A report is considered serious if at least one of the 
following is reported: death, life-threatening illness, hospitalization or prolongation of 
hospitalization, or permanent disability [68]. In addition, CDC and FDA scientists use 
statistical techniques to check for disproportional reporting in the VAERS database for 
deaths and other adverse events for individual types and brands of vaccines [69]. If CDC or 
FDA were to detect a potential new safety problem with MMR or any other US licensed 
vaccine, this “signal” would be further assessed and regulatory and/or public health action 
would be taken, if necessary.
With respect to the recent claims of deaths caused by MMR vaccine [5–7], drawing broad 
cause and effect conclusions between vaccination and deaths based on spontaneous reports 
to VAERS, some of which might be anecdotal or second hand, is not a scientifically valid 
practice. In fact, a review of the VAERS data reveals that many of the death reports for 
MMR vaccine involved children with serious preexisting medical conditions or were likely 
unrelated to vaccination (e.g., accidents). These complete VAERS reports and any 
accompanying medical records, autopsy reports and death certificates have been reviewed in 
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depth by FDA and CDC physicians and no concerning patterns have emerged that would 
suggest a causal relationship with the MMR vaccine and death.
The evidence for the safety and effectiveness of vaccines routinely given to children and 
adults in the Unites States is overwhelmingly favorable. In the case of MMR vaccine, this 
includes preventing hundreds of potential measles-related deaths each year [34]. Any 
discussion of the true risks of vaccination should be balanced by acknowledgment of the 
well-established benefits of vaccines in preventing disease, disability and deaths from 
infectious diseases.
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